The Recombinant Coagulation Factors Market is projected to reach $24.21 billion by 2030, at a CAGR of 8.6% from 2023 to 2030. Recombinant coagulation factors differ from plasma-derived factors due to production technology which involves recombinant DNA technology. These factors have a very low risk for transmission blood-borne transmission of infectious diseases, and their use should eradicate the threat of infection from viruses such as hepatitis C and the human immunodeficiency virus. Thus, they are majorly applicable to bleeding disorders like hemophilia.
The increasing prevalence of hemophilia and other bleeding disorders, growing R&D for coagulation factors, growing awareness about the benefits of the recombinant coagulation factors and increasing prophylactic treatment for hemophilia across the globe are driving the growth of the recombinant coagulation factors market. Furthermore, the potential emerging economies and rising healthcare expenditure are expected to offer significant growth opportunities for the recombinant coagulation factors market.
However, the high cost of recombinant factors compared to plasma-derived ones and the limited accessibility and availability of recombinant clotting factors in developing & underdeveloped countries are expected to restrain the growth of this market. Additionally, manufacturing challenges in the production of recombinant clotting factors, stringent regulatory requirements, lack of reimbursement in some countries, and lack of awareness among patients are some of the challenges to the growth of this market.
Hemophilia A and B are the most common severe hereditary hemorrhagic disorders. These disorders are caused due to coagulation factor VIII and factor IX protein deficiency. Such deficient patients have prolonged bleeding with or without trauma, depending on the factor activity. According to National Center for Biotechnology Information (NCBI) data, in September 2022, the estimated frequency of hemophilia was about 1 in 10,000 live births, and the number of people worldwide living with hemophilia was about 4,00,000. Hemophilia A is more prevalent, about 80-85% of the total hemophilia population. It is present in 1 in 5,000 live male births, whereas hemophilia B is present in 1 in 30,000 live male births.
Thus, to tackle this disorder, recombinant coagulation factors are gaining popularity. The wide availability of recombinant factor VIII, viral inactivation, and better screening technology make the product and treatment safer. Thus, despite the availability of plasma-derived factor concentrates, about 75% of patients with hemophilia worldwide receive recombinant factor VIII products since they are much safer. Thus, the effectiveness of these products supports better treatment for hemophilic patients, driving the growth of this market.
Preference for Recombinant Coagulation Factors over Plasma-derived Factors Provide Opportunity for the Players in this Market
Plasma-derived concentrates are made from human blood donated by healthy volunteers and screened for safety. Recombinant factor products are made in a laboratory using recombinant technology. These products are not made from human blood. Since recombinant factor products are manufactured in the laboratory, it avoids the risk of transmission of blood-borne viruses.
Previously, patients with bleeding disorders like hemophilia were treated with plasma concentrates. But haemophilia patients treated with plasma concentrates prepared from pooled plasma were found to be at an enormously high risk of HIV infection because there was no way to screen plasma or plasma donors for HIV. Thus, traditionally, about 70-75% of patients with severe haemophilia are found to have HIV. Manufacturers provide virus inactivation methods that improve plasma concentrates. However, the perception of patients and treaters of the potential risk of blood-borne virus transmission still remains high. This led to the emergence of recombinant coagulation factors. This offers a safer option than plasma-derived products because they avoid potential blood-borne transmission of infectious diseases. Thus, avoid secondary infection risk; hence, the use of recombinant products over plasma-derived ones provides growth opportunities for the players in this market.
Click here to: Get a Free Sample Copy of this report
In 2023, the Recombinant Factor VIII Segment is Expected to Dominate this Market
Based on type, the recombinant coagulation factors market is segmented into recombinant factor VIII, recombinant factor IX, and other types. In 2023, the recombinant factor viii segment is expected to account for the largest share of this market. The large market share of the recombinant factor VIII segment is attributed to advancements in recombinant technology, high demand for recombinant factor VIII due to a large patient pool of hemophilia A patients, and growing awareness about the benefits of recombinant coagulation factors.
In 2023, the Hemophilia A Segment is Expected to Dominate this Market
Based on application, the recombinant coagulation factors market is segmented into hemophilia A, hemophilia B, and other applications. In 2023, the hemophilia A segment is expected to account for the largest share of the recombinant coagulation factors market. The large market share of this segment is attributed to factors such as a higher number of hemophilia A patients compared to hemophilia B, favorable government initiatives to support the treatment of hemophilia A, and the rising global prevalence of hemophilia.
In 2023, the Hospitals & Clinics Segment is Expected to Dominate this Market
Based on end user, the recombinant coagulation factors market is segmented into hospitals & clinics and clinical research laboratories. In 2023, the hospitals & clinics segment is expected to account for the largest share of the recombinant coagulation factors market. The large market share of this segment is attributed to the increased adoption of recombinant coagulation factors in hospitals for the treatment of coagulation disorders, rising healthcare expenditure, and rising awareness among healthcare professionals.
Asia-Pacific: Fastest-growing Regional Market
The growth of this market is driven by the increasing hereditary disorders, the increasing investments in healthcare in developing countries such as China and India, and the growing preference for recombinant technology owing to advantages compared to traditional are driving the growth of the recombinant coagulation factors market in Asia-Pacific.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market players in the past few years. The key players profiled in the recombinant coagulation factors market report are Baxter International Inc. (U.S.), Grifols, S.A. (Spain), CSL Limited (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Inc. (U.S.), Bayer AG (Germany), Kedrion S.p.A. (Italy), Emergent BioSolutions (U.S.), and Pfizer Inc. (U.S.).
Scope of the Report:
Recombinant Coagulation Factors Market Assessment, by Type
Recombinant Coagulation Factors Market Assessment, by Source
Recombinant Coagulation Factors Market Assessment, by Application
Recombinant Coagulation Factors Market Assessment, by End User
Recombinant Coagulation Factors Market Assessment, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the recombinant coagulation factors market and analyzes the market sizes & forecasts based on type, source, application, and end user. This report also involves the value analysis of various segments and subsegments of the recombinant coagulation factors market at the regional and country levels.
The recombinant coagulation factors market is projected to reach $24.21 billion by 2030, at a CAGR of 8.6% during the forecast period.
Based on type, in 2023, the recombinant factor VIII segment is expected to account for the largest share of the market due to increased demand for the treatment of hemophilia A and advancement in recombinant technology.
Based on application, the hemophilia A segment is projected to register the highest CAGR during the forecast period. The growth of this segment is driven by the increasing incidence of hemophilia and the rise in diagnosis rate leading to the wide adoption of recombinant coagulation factors.
The increasing prevalence of hemophilia and other bleeding disorders, growing R&D for coagulation factors, growing awareness about the benefits of the recombinant coagulation factors and increasing prophylactic treatment for hemophilia across the globe are driving the growth of the recombinant coagulation factors market.
Furthermore, the potential emerging economies and rising healthcare expenditure are expected to offer significant growth opportunities for the recombinant coagulation factors market.
The key players profiled in the recombinant coagulation factors market study are Baxter International Inc. (U.S.), Grifols, S.A. (Spain), CSL Limited (Australia), Octapharma AG (Switzerland), Novo Nordisk A/S (Denmark), Biogen Inc. (U.S.), Bayer AG (Germany), Kedrion S.p.A. (Italy), Emergent BioSolutions (U.S.), and Pfizer Inc. (U.S.).
Emerging economies such as China and India are projected to offer significant growth opportunities to the market players due to rising healthcare expenditure, large patient volume suffering from hemophilia, and the high market expansion potential in these countries.
This report provides pre & post COVID-19 market estimates.
1. Market Scope & Definition
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Hemophilia and Other Bleeding Disorders
4.2.2. Growing R&D for Coagulation Factors
4.2.3. Growing Awareness About the Benefits of Recombinant Coagulation Factors
4.2.4. Increasing Prophylactic Treatment for Hemophilia
4.3. Restraints
4.3.1. High Cost of Recombinant Factors Compared to Plasma-derived Products
4.3.2. Limited Accessibility and Availability of Recombinant Clotting Factors in Developing & Underdeveloped Countries
4.4. Opportunities
4.4.1. Potential Emerging Economies
4.4.2. Rising Healthcare Expenditure
4.5. Challenge
4.5.1. Manufacturing Challenges in the Production of Recombinant Clotting Factors
4.5.2. Stringent Regulatory Requirements
4.5.3. Lack of Reimbursement in Some Countries
4.5.4. Lack of Awareness Among Patients
4.6. Pricing Analysis
4.7. Recombinant Coagulation Factors Pipeline Analysis
4.8. Regulatory Analysis
4.9. Industry & Technology Trends
5. Recombinant Coagulation Factors Market Assessment—by Type
5.1. Overview
5.2. Recombinant Factor VIII
5.3. Recombinant Factor IX
5.4. Other Types
6. Recombinant Coagulation Factors Market Assessment—by Source
6.1. Introduction
6.2. Chinese Hamster Ovary (CHO) Cell Line
6.3. Human Embryonic Kidney (HEK) Cell Line
6.4. Other Sources
7. Recombinant Coagulation Factors Market Assessment—by Application
7.1. Introduction
7.2. Hemophilia A
7.3. Hemophilia B
7.4. Other Applications
8. Recombinant Coagulation Factors Market Assessment—by End User
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Clinical Research Laboratories
9. Recombinant Coagulation Factors Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4 Rest of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Vendor Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis (2022)
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis of Top 5 Companies)
11.1. Baxter International Inc.
11.2. Grifols, S.A.
11.3. CSL Limited
11.4. Octapharma AG
11.5. Kedrion S.p.A.
11.6. Pfizer Inc.
11.7. Novo Nordisk A/S
11.8. Bayer AG
11.9. Biogen, Inc.
11.10. Emergent BioSolutions
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Recombinant Coagulation Factors Market Drivers: Impact Analysis (2023–2030)
Table 2 Global Recombinant Coagulation Factors Market Restraint: Impact Analysis (2023–2030)
Table 3 Global Recombinant Coagulation Factors Market Opportunities: Impact Analysis (2023–2030)
Table 4 Global Recombinant Coagulation Factors Market Challenges: Impact Analysis (2023–2030)
Table 5 Global Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 6 Global Recombinant Factor VIII Market, by Country/Region, 2021–2030 (USD Million)
Table 7 Vendors Offering Recombinant Factor VIII
Table 8 Global Recombinant Factor IX Market, by Country/Region, 2021–2030 (USD Million)
Table 9 Vendors Offering Recombinant Factor IX
Table 10 Global Other Recombinant Factor Types Market, by Country/Region, 2021–2030 (USD Million)
Table 11 Global Recombinant Coagulation Factors Market, by Source, 2021–2030 (USD Million)
Table 12 Global Chinese Hamster Ovary (CHO) Cell Line Market, by Type, 2021–2030 (USD Million)
Table 13 Global Human Embryonic Kidney (HEK) Cell Line Market, by Country/Region, 2021–2030 (USD Million)
Table 14 Global Other Sources Market, by Country/Region, 2021–2030 (USD Million)
Table 15 Global Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 16 Global Hemophilia A Market, by Country/Region, 2021–2030 (USD Million)
Table 17 Global Hemophilia B Market, by Country/Region, 2021–2030 (USD Million)
Table 18 Global Other Applications Market, by Country/Region, 2021–2030 (USD Million)
Table 19 Global Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 20 Global Recombinant Coagulation Factors Market for Hospitals & Clinics, by Type, 2021–2030 (USD Million)
Table 21 Global Recombinant Coagulation Factors Market for Clinical Research Laboratories, by Country/Region, 2021–2030 (USD Million)
Table 22 Global Recombinant Coagulation Factors Market, by Country/Region, 2021–2030 (USD Million)
Table 23 North America: Recombinant Coagulation Factors Market, by Country, 2021–2030 (USD Million)
Table 24 North America: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 25 North America: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 26 North America: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 27 North America: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 28 U.S.: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 29 U.S.: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 30 U.S.: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 31 U.S.: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 32 Canada: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 33 Canada: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 34 Canada: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 35 Canada: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 36 Europe: Recombinant Coagulation Factors Market, by Country, 2021–2030 (USD Million)
Table 37 Europe: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 38 Europe: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 39 Europe: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 40 Europe: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 41 Germany: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 42 Germany: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 43 Germany: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 44 Germany: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 45 France: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 46 France: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 47 France: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 48 France: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 49 U.K.: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 50 U.K.: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 51 U.K.: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 52 U.K.: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 53 Italy: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 54 Italy: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 55 Italy: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 56 Italy: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 57 Spain: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 58 Spain: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 59 Spain: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 60 Spain: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 61 RoE: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 62 RoE: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 63 RoE: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 64 RoE: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 65 Asia-Pacific: Recombinant Coagulation Factors Market, by Country, 2021–2030 (USD Million)
Table 66 Asia-Pacific: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 67 Asia-Pacific: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 68 Asia-Pacific: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 69 Asia-Pacific: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 70 China: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 71 China: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 72 China: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 73 China: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 74 India: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 75 India: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 76 India: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 77 India: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 78 Japan: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 79 Japan: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 80 Japan: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 81 Japan: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 82 RoAPAC: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 83 RoAPAC: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 84 RoAPAC: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 85 RoAPAC: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 86 Latin America: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 87 Latin America: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 88 Latin America: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 89 Latin America: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 90 Middle East & Africa: Recombinant Coagulation Factors Market, by Type, 2021–2030 (USD Million)
Table 91 Middle East & Africa: Recombinant Coagulation Factors Market, by Source 2021–2030 (USD Million)
Table 92 Middle East & Africa: Recombinant Coagulation Factors Market, by Application, 2021–2030 (USD Million)
Table 93 Middle East & Africa: Recombinant Coagulation Factors Market, by End User, 2021–2030 (USD Million)
Table 94 Recent Developments, by Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Estimation
Figure 7 Global Recombinant Coagulation Factors Market, by Type, 2023 Vs. 2030 (USD Million)
Figure 8 Global Recombinant Coagulation Factors Market, by Source, 2023 Vs. 2030 (USD Million)
Figure 9 Global Recombinant Coagulation Factors Market, by Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global Recombinant Coagulation Factors Market, by End User, 2023 Vs. 2030 (USD Million)
Figure 11 Global Recombinant Coagulation Factors Market, by Geography, 2023 Vs. 2030 (USD Million)
Figure 12 North America: Recombinant Coagulation Factors Market Snapshot
Figure 13 Asia-Pacific: Recombinant Coagulation Factors Market Snapshot
Figure 14 Europe: Recombinant Coagulation Factors Market Snapshot
Figure 15 Key Growth Strategies Adopted by Leading Players, 2020–2023
Figure 16 Recombinant Coagulation Factors: Competitive Benchmarking, by Type
Figure 17 Recombinant Coagulation Factors: Competitive Benchmarking, by Geography
Figure 18 Market Share Analysis: Recombinant Coagulation Factors Industry, 2022
Figure 19 Baxter International Inc.: Financial Overview (2022)
Figure 20 Grifols, S.A.: Financial Overview (2022)
Figure 21 CSL Limited: Financial Overview (2022)
Figure 22 Octapharma AG: Financial Overview (2022)
Figure 23 Kedrion S.p.A.: Financial Overview (2022)
Figure 24 Pfizer Inc.: Financial Overview (2022)
Figure 25 Novo Nordisk A/S: Financial Overview (2022)
Figure 26 Bayer AG: Financial Overview (2022)
Figure 27 Biogen Inc.: Financial Overview (2022)
Figure 28 Emergent BioSolutions: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Jul-2020
Published Date: Jul-2022
Published Date: Sep-2022
Published Date: Sep-2022
Published Date: Jul-2023
